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There is a great interest in developing cerebrospinal fluid (CSF) biomarkers for diagnosis
and prognosis of Parkinson’s disease (PD). CSF alpha synuclein (α-syn) species, namely
total and oligomeric α-syn (t-α-syn and o-α-syn), have shown to be of help for PD diagnosis.
Preliminary evidences show that the combination of CSF t-α-syn and classical Alzheimer’s
disease (AD) biomarkers—β-amyloid 1–42 (Aβ42), total tau (t-tau), phosphorylated tau
(p-tau)—differentiate PD patients from controls, and that reduced levels of Aβ42 represent
a predictive factor for development of cognitive deterioration in PD. In this prospective
study carried out in 44 PD patients and 25 neurological controls we wanted to verify
whether the combination of CSF α-synuclein species—t-α-syn and o-α-syn—and classical
AD biomarkers may help in differentiating PD from neurological controls, and if these
biomarkers may predict cognitive decline. The median of follow-up duration was 3 years
(range: 2–6 years). Mini Mental State Examination (MMSE) and Montreal Cognitive
Assessment (MoCA) were used for monitoring cognitive changes along time, being
administered once a year. Oligo/total α-syn ratio (o/t-α-syn ratio) confirmed its diagnostic
value, significantly contributing to the discrimination of PD from neurological controls. A
greater diagnostic accuracy was reached when combining o/t-α-syn and Aβ42/tau ratios
(Sens = 0.70, Spec = 0.84, AUC = 0.82; PPV = 0.89, NPV = 0.62, LR+ = 4.40, DOR =
12.52). Low CSF Aβ42 level was associated with a higher rate of MMSE andMoCA decline,
confirming its role as independent predictive factor for cognitive decline in PD. None of the
other biomarkers assessed (t-tau, p-tau, t-α-syn and o-α-syn) showed to have prognostic
value. We conclude that combination of CSF o/t-α-syn and Aβ42/tau ratios improve the
diagnostic accuracy of PD. PD patients showing low CSF Aβ42 levels at baseline are more
prone to develop cognitive decline.
Keywords: cerebrospinal fluid biomarkers, alpha synuclein, total tau, phosphorylated tau, Aβ42, Parkinson’s
disease, cognitive decline
INTRODUCTION
Parkinson’s disease (PD) is a common neurodegenerative disor-
der evolving, in a substantial proportion of patients, to dementia.
Although it is defined as a typical movement disorder and its
diagnosis is mainly based on motor-related clinical criteria, other
functional domains are also involved. Accordingly, post-mortem
findings of alpha-synuclein (α-syn) pathology—the histopatho-
logic hallmark of PD—show that the involvement of the dorsal
motor nucleus of the vagal nerve and the olfactory bulb takes
place much earlier before midbrain involvement (Braak et al.,
2003).
PD is a complex neurodegenerative disorder in which many
different pathophysiological processes take place, such as pro-
tein aggregation, oxidative damage and lysosomal dysfunction
(Parnetti et al., 2013). Concomitant pathologies (i.e., Alzheimer
and Lewy bodies pathologies) resulting from the mutual interac-
tion between Aβ42, tau and α-syn during the course of the disease
have major role in the neuropathological processes underlying
dementia in PD (Tsigelny et al., 2008; Ciaccioli et al., 2013). In
PD the spread of fibrillar α-syn pathology from the brainstem to
limbic and neocortical structures, and the cortical deposition of
β-amyloid plaques, represent major events (Compta et al., 2011;
Irwin et al., 2012). Co-occurrence of tau and α-syn pathology has
been found in neurons of brains affected by tauopathies and synu-
cleinopathies, including PD (Vekrellis et al., 2011). Also, α-syn
causes aggregation and polymerization of tau, which then induces
the formation of intracellular amyloid-tau inclusions (Waxman
and Giasson, 2011).
Since molecular changes in the brain are reflected in cere-
brospinal fluid (CSF) composition, the CSF represents an ideal
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source for biomarkers of different pathophysiological processes
characterizing the early phases of the disease, when the clinical
diagnosis is more challenging. For example, Aβ42, total tau (t-tau)
and phosphorylated tau (p-tau) are state markers of Alzheimer’s
disease (AD), as they reliably reflect AD pathology also in pre-
dementia phases. This knowledge has been translated into opera-
tional diagnostic criteria (Dubois et al., 2010). Analogously, there
is great interest for improving early diagnosis in PD, hopefully in
the pre-motor phases, as well as for detecting PD patients at risk
of dementia.
Currently, detection of reliable CSF biomarkers for PD is
under intensive investigation. Several recent studies have explored
the potential use of CSF total α-syn (t-α-syn) as a putative PD
biomarker. A clear trend of lower CSF t-α-syn levels in PD and
other synucleinopathies has been consistently reported (Tokuda
et al., 2006; Noguchi-Shinohara et al., 2009; Spies et al., 2009;
Hong et al., 2010; Mollenhauer et al., 2011; Parnetti et al., 2011;
Aerts et al., 2012; Tateno et al., 2012), although with a large
overlap between the PD and control groups (Noguchi-Shinohara
et al., 2009; Spies et al., 2011). Therefore, the measurement of
CSF t-α-syn doesn’t seem to have enough specificity to correctly
discriminate patients with synucleinopathies from normal indi-
viduals or other neurodegenerative diseases. The measurement
in CSF of other α-syn species, namely soluble oligomers (o-α-
syn) has improved the discrimination between PD and other
diseases. O-α-syn levels are elevated in brain homogenates in PD
and dementia with Lewy bodies compared with normal brains
(Paleologou et al., 2009) suggesting a role for o-α-syn in PD
pathogenesis. CSF o-α-syn levels and o/t-α-syn ratio have been
consistently found to be significantly higher in PD patients as
compared to other neurological disorders, with good sensitiv-
ity and specificity, as confirmed in independent reports (Tokuda
et al., 2010; Park et al., 2011; Sierks et al., 2011; Parnetti et al.,
2014). The high risk of cognitive impairment in PD also calls for
biomarkers able to predict dementia onset. Many studies have
focused on classical AD CSF biomarkers (Parnetti et al., 2008;
Compta et al., 2009; Alves et al., 2010; Montine et al., 2010;
Siderowf et al., 2010; Leverenz et al., 2011) and most of them have
identified the reduction of CSF Aβ42 levels as a prognostic factor
for cognitive impairment in PD. Data on the possible relation-
ship between α-syn species and the risk of dementia in PD are
still scanty.
In this study we evaluated both the diagnostic accuracy and the
capability in predicting cognitive decline of CSF AD biomarkers
(Aβ42, t-tau, p-tau and Aβ42/t-tau ratio) and α-syn species (t-α-
syn, o-α-syn and o/t-α-syn ratio) in PD patients and neurological
controls with a median follow up duration of 3 years.
MATERIALS AND METHODS
PATIENTS
The subjects included in this study (44 PD, 25 neurological con-
trols) were consecutively recruited between 2007 and 2011 and
followed-up. They underwent a baseline clinical examination
by experienced neurologists, detailed neuropsychological testing,
blood chemistry, neuroimaging (computed tomography and/or
magnetic resonance imaging), and lumbar puncture. CSF was
collected according to the hospital standard protocol and with
the local ethical committee approval, after informed written con-
sent was given by the patient. All PD patients fulfilled the United
Kingdom Parkinson’s Disease Society Brain Bank clinical diag-
nostic criteria. All of them were treated with L-DOPA and the
great majority (39 out of 44) were also taking DA-agonists. PD
patients had good control of motor symptoms (mean UPRDS-III
25.39 ± 12.97), and were functionally independent or minimally
dependent (Hoehn and Yahr, 1–2.5). Disease duration was cal-
culated from the onset of the first motor symptoms to the time
of lumbar puncture. As a control group, 25 cognitively normal
age-matched subjects who underwent lumbar puncture as a part
of diagnostic work up for other neurological conditions (OND)
were recruited to our study. The OND group included: primary
headache (n = 15), postural instability (n = 3), seizures (n = 2)
and polyneuropathy (n = 5). Follow-up visits included clinical
examination and neuropsychological testing carried out yearly
by means of MMSE (Folstein et al., 1975), a popular screening
tool mostly measuring cortical functions with special attention
to memory, and MoCA (Gill et al., 2008), another screening tool
assessing executive functions.
CSF SAMPLING
Lumbar puncture was performed between 8:00 and 10:00 A.M.,
after an overnight fast. CSF (10mL) was collected in sterile
polypropylene tubes, centrifuged for 10min at 2000× g, and
0.5-mL aliquots were immediately frozen at −80◦C. None of
the samples was contaminated by blood during the procedure
(samples showing an erythrocyte count >500/mm3 were not
included in the study). CSF Aβ42, t-tau and p-tau were mea-
sured with ELISA assays (Innotest βAmyloid 1–42, hTAU-Ag,
p-TAU 181 Ag; Innogenetics NV, Gent, Belgium, now Fujirebio).
For CSF α-syn, 0.5mL samples were thawed on ice and then
divided into aliquots of 110μL in siliconized tubes containing a
cocktail of protease inhibitors, including AEBSF, aprotinin, E-64,
EDTA, and leupeptin (Calbiochem-Novabiochem Corporation,
San Diego, CA), and 0.05% Tween 20, and the samples were
then stored at −80◦C until used in the immunoassay for α-syn.
While CSF t-α-syn is expressed as ng/mL, CSF o/t-α-syn ratio
is expressed in CPS (counts per second). All the samples were
obtained at the Section of Neurology, Perugia General Hospital,
according to the protocol approved by the Regional Ethical
Committee (Prot. N. 19369/AV), after informed written consent
was obtained.
IMMUNOASSAY FOR α-SYNUCLEIN IN CSF
Total and oligomeric CSF α-syn were measured as previ-
ously reported (Tokuda et al., 2006). Briefly, for CSF t-α-
syn anti-human α-syn monoclonal antibody (clone Syn211)
(Santa Cruz Biotechnology, USA) was used for capturing while
the anti-human α-syn polyclonal antibody FL-140 (Santa Cruz
Biotechnology, USA) was used for antigen detection. The stan-
dard curve for the ELISA assay was constructed using recombi-
nant human α-syn solution at different concentrations diluted
in blocking buffer. For α-syn oligomers, the antibody clone
Syn211 was used for capturing, while biotinylated Syn211 (Santa
Cruz Biotechnology, USA) was used for antigen detection. The
plate was incubated with 50μL/well of ExtrAvidin-Peroxidase
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(Sigma-Aldrich, UK) and with the enhanced chemiluminescent
substrate. For both immunoassays, the samples were screened
in blind fashion and were randomly tested. A series of internal
controls were run to check for run-to-run variations.
DATA ANALYSIS
Statistical analyses were performed using R software v. 2.15
(R Core Team, 2013). Continuous variables were described
by median and ranges since data distributions were skewed.
Correlations were calculated using Spearman’s Rho (r). Kruskal-
Wallis test was initially used for comparisons between the two
diagnostic groups (p < 0.05). The accuracy of the diagnostic
value of the biomarkers was assessed by area under the curve
(AUC) of the receiver operating characteristic (ROC) curve
(Robin et al., 2011; Eusebi, 2013). Cut-off values were calculated
using sensitivity and specificity values that maximized Youden’s
index (sensitivity + specificity − 1). For evaluating the role of
multiple biomarkers a multivariable logistic regression approach
was used. With the aim to find the best predictors of PD to be
included in the final model, we considered all the CSF enzyme
activities which had already shown significant differences between
OND and PD groups after the univariate analysis.
Multivariate linear regression analysis was used for analyzing
the biomarker role in predicting cognitive decline. Change in
MMSE and MoCA score were considered as dependent variables.
Multiple imputations for missing values were performed in mul-
tivariable analyses (Rubin, 1987). Missing data were filled in five
times to generate five complete data sets. The completed datasets
were analyzed by using the mixed-effects model and the results
were combined for the inference.
RESULTS
DESCRIPTIVE ANALYSIS
Demographic data, clinical features, and biomarkers values are
listed in Table 1. As expected, no significant difference between
PD and OND groups was found with respect to age, gender, and
follow-up duration. Both MMSE and MoCA scores were signifi-
cantly lower at baseline (p = 0.009 and p = 0.025, respectively)
and after follow-up (p = 0.004 and p < 0.001, respectively).
Follow-up observations refer to the last visit carried out.
CSF BIOMARKERS IN DIAGNOSTIC GROUPS
Values of CSF biomarkers showed substantial overlap between
the two groups (Table 2 and Figure 1). Although the differences
did not reach the statistical significance, in PD group median
Aβ42 levels were higher as opposite to lower median t-tau lev-
els. As a consequence, Aβ42/t-tau ratio was significantly increased
in the PD group with respect to OND subjects (p < 0.01,
Table 2). Analogously to previous observation (Balducci et al.,
2007), a significant decrease of t-α-syn (p = 0.015) and an
increase of o-α-syn levels (p = 0.041) were found in PD group
(Table 2). Interestingly the o/t-α-syn ratio greatly improved the
discrimination between PD and OND groups (p < 0.001,
Table 2). ROC analysis showed a sensitivity of 0.82 and a speci-
ficity of 0.56 for Aβ42/t-tau ratio. T-α-syn had a sensitivity of
0.59 and a specificity of 0.80. O-α-syn disclosed a sensitivity
of 0.89 and a specificity of 0.48. O/t-α-syn ratio reached the
best diagnostic performance having a sensitivity of 0.82 and a
specificity of 0.64.
In Table 3 the correlation analysis for all the CSF biomarkers
considered is reported. Interestingly, in the PD group, an inverse
association between t-α-syn and t-tau was found. Such a negative
correlation was also observed in the OND group, where it did not
reach the statistical significance. As expected, in the OND group
a significant positive association between t-α-syn and Aβ42/tau
ratio was observed.
Table 4 reports the correlation analysis between CSF biomark-
ers and clinical parameters in OND and PD groups. In PD
t-tau was positively correlated with the H&Y stage, as oppo-
site to the Aβ42/t-tau ratio, which was inversely related to H&Y.
Cognitive changes along time were measured as points lost in
MMSE and MoCA scores between baseline and follow-up vis-
its. In PD Aβ42 was negatively correlated with decline in MMSE
and MoCA scores. Aβ42/t-tau ratio was negatively correlated with
decrease in MMSE score. In OND group no significant correla-
tion was found between CSF parameters and decrease in MMSE
and MoCA scores.
MULTIPLE BIOMARKERS EVALUATION IN DIAGNOSTIC GROUPS
In order to assess the diagnostic performance of multiple
biomarkers combination a logistic regression approach was used.
Table 5 shows a summary of the best model according to several
measures of test effectiveness, including sensitivity and specificity,
positive and negative predictive values, positive/negative likeli-
hood ratio, AUC and diagnostic odds ratio (DOR). The model
included Aβ42/t-tau and o/t-α-syn ratios, which together reached
a specificity of 84% and a sensitivity of 70%.
Figure 2 shows how the model separates PD patients from
OND, allowing for a good discrimination of PD and how the
model predictions reach a superior diagnostic performance with
respect to the o/t-α-syn or Aβ42/t-tau ratios, separately.
CSF BIOMARKERS FOR PREDICTING COGNITIVE DECLINE IN PD
As reported in the previous section, Aβ42 and the Aβ42/t-tau
ratio were the only parameters showing a correlation with MMSE
and MoCA scores. To investigate the relationship between the
decrease of these two neuropsychological measurements with
Aβ42 and Aβ42/t-tau ratio, a multivariate linear regression model
was applied, adjusting for the baseline values and follow-up dura-
tion (Table 6). MMSE score decrease confirmed to be significantly
associated with low CSF Aβ42 levels at baseline; the same trend
was also observed for MoCA scores; Aβ42/t-tau ratio was not
significantly associated with cognitive decline.
DISCUSSION
As in other neurodegenerative disorders, PD is characterized by a
large time gap between the beginning of neurodegenerative pro-
cesses and the onset of clinical neurological manifestations. The
disease’s natural history includes a first asymptomatic stage, fol-
lowed by a long pre-motor phase; finally, when the classical motor
symptoms appear, the majority of nigral dopaminergic neurons
are already affected by degeneration. The classical diagnostic cri-
teria for PD mostly rely on motor symptoms, making the formu-
lation of an early diagnosis very challenging. Another challenge
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Table 1 | Demographic data and clinical features for OND and PD.
OND PD p-value
N 25 44 –
Age 58 (R 31–78; IQR 47–73) 66 (R 41–79; IQR 57.8–72) 0.117
Sex (M) 9 (36.0%) 27 (61.4%) 0.076
PD duration (years) – 3 (R 1–9; IQR 1–5.25) –
Hoehn and Yahr score – 2 (R 1–4; IQR 1.5–2.5) –
MMSE score at baseline 29 (R 27–30; IQR 28–30) 27 (R 20–30; IQR 25.8–30) 0.009
MMSE score at follow-up 28 (R 26–30; IQR 27–30) 26.5 (R 17–30; IQR 23.8–29) 0.004
MoCA score at baseline 28 (R 27–30; IQR 25.5–28.5) 25.5 (R 17–30; IQR 22.8–28) 0.025
MoCA score at follow-up 26 (R 20–29; IQR 24–27) 22 (R 10–28; IQR 18.75–25) <0.001
Follow-up duration (years) 4 (R 2–7; IQR 3–5) 2 (R 1–7; IQR 2–6) 0.197
P-values, count, and percentages for sex and medians, ranges (R), interquartile ranges (IQR) for the other variables.
Table 2 | CSF biomarkers in PD and OND.
OND PD p-value AUC Sens Spec cut-off
Aβ42 530 (431–752) 693 (493–852) 0.057 0.64 (0.51–0.78) 0.59 0.72 636.00
t-tau 194 (117–257) 146 (109–204) 0.085 0.63 (0.48–0.77) 0.64 0.68 159.00
p-tau 19 (11–24) 19.5 (9.75–30.25) 0.793 0.52 (0.38–0.66) 0.36 0.80 25.50
Aβ42/t-tau ratio 2.85 (1.88–4.88) 4.70 (3.47–6.38) 0.004 0.71 (0.59–0.84) 0.82 0.56 3.15
t-α-syn 36.5 (25.8–49.6) 22.15 (11.86–38.64) 0.015 0.68 (0.55–0.81) 0.59 0.80 24.45
o-α-syn 3139 (1500–6140) 4838 (3049–8141) 0.041 0.72 (0.59–0.84) 0.89 0.48 2565.50
o/t-α-syn ratio 0.021 (0.014–0.043) 0.061 (0.034–0.175) <0.001 0.78 (0.67–0.89) 0.82 0.64 0.03
Median values with interquartile ranges (IQR); ROC analysis summary with AUC (95% CI), sensitivity and specificity.
for the research focused on this disorder is the understand-
ing of the mechanisms underlying the development of dementia
taking place in a subgroup of parkinsonian patients. It would
be very important to have the possibility to individuate those
patients at risk to develop this devastating complication to initiate
possible protective pharmacological and non-pharmacological
interventions. Thus, the availability of objective measures such as
reliable “biomarkers,” indicators of biological/pathogenetic pro-
cesses, will be of great importance both for diagnostic accuracy
and prognostic evaluation.
In this context, CSF analysis might be of great importance
since CSF dynamically reflects the pathophysiological processes
taking place in the brain. At present, CSF biomarkers are a routine
analysis for early diagnosis of AD. Accordingly, increasing interest
is focused on CSF biomarkers in PD, with major expectations on
α-syn species and other misfolding proteins, namely β-amyloid
and tau. With respect to diagnostic performance, data available
so far indicate that there is not a unique ideal CSF biomarker,
rather the combination of molecules related to different patho-
physiological pathways involved in PD may represents a good
strategy for obtaining a more accurate diagnosis (Parnetti et al.,
2014). Concerning the prediction of cognitive decline in PD, the
most consistent role as predictive factor is played by low CSF
Aβ42 levels (Parnetti et al., 2008; Alves et al., 2010; Siderowf et al.,
2010; Leverenz et al., 2011) although also tau species have been
postulated to represent prognostic factors (Zhang et al., 2013).
Interestingly, a recent investigation (Kang et al., 2013) carried
out in drug-naïve patients with early PD, showed slightly lower
CSF levels of both t-tau and t-α-syn in PD compared to healthy
controls. This finding offered the Authors the opportunity to
speculate that the interaction between tau proteins and α-synmay
limit the release of tau proteins into CSF.
In this investigation we assessed both the diagnostic accuracy
and the performance in predicting cognitive decline of the combi-
nation of CSF AD biomarkers (Aβ42, t-tau, p-tau, and Aβ42/t-tau
ratio) and α-syn species (t-α-syn, o-α-syn, and o/t-α-syn ratio) in
a cohort of PD patients and neurological controls followed up for
2–6 years (median follow-up duration: 3 years).
With respect to the diagnostic performance of the biomark-
ers considered, none of them demonstrated acceptable values in
terms of sensitivity and specificity when taken separately. Aβ42/t-
tau and o/t-α-syn ratios showed good sensitivity (0.82) but low
specificity (0.56 and 0.64, respectively). While the usefulness of
o/t-α-syn ratio in discriminating PD and controls has already
been reported in recent investigations (Tokuda et al., 2010; Park
et al., 2011; Sierks et al., 2011; Parnetti et al., 2014), the Aβ42/t-
tau ratio deserves some comments. Interestingly, in the PD group,
we found slightly higher values of Aβ42 together with lower val-
ues of t-tau as compared to OND group. As a consequence, the
mean value of Aβ42/t-tau ratio was significantly higher in PD
patients with respect to the OND group. This may be due to the
fact that our control group was not including healthy subjects,
being composed by patients with other neurological diseases.
Interestingly, reduced CSF Aβ42 levels at baseline represented a
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FIGURE 1 | Boxplots of CSF biomarkers values observed in PD and OND cohorts. The horizontal bold lines indicate the medians; the lower part of boxes
indicates the first quartile and the upper part the third quartile; the dashed vertical lines indicate the range of values.
Table 3 | Spearman’s rank correlation matrix for CSF biomarkers in PD and OND groups.
Aβ42 t-tau p-tau Aβ42/tau ratio t-asyn o-asyn o/t-asyn ratio
PD Aβ42 1.00
t-tau 0.07 1.00
p-tau 0.25 0.71*** 1.00
Aβ42/t-tau ratio – – −0.44** 1.00
t-α-syn −0.25 −0.33* −0.25 0.13 1.00
o-α-syn −0.12 −0.15 −0.14 0.07 0.06 1.00
o/t-α-syn ratio 0.15 0.11 −0.01 −0.02 – – 1.00
OND Aβ42 1.00
t-tau 0.28 1.00
p-tau 0.11 0.56** 1.00
Aβ42/t-tau ratio – – −0.41* 1.00
t-α-syn 0.24 −0.25 −0.24 0.43* 1.00
o-α-syn 0.01 −0.14 −0.08 0.04 0.21 1.00
o/t-α-syn ratio −0.34 −0.03 −0.04 −0.32 – – 1.00
*p < 0.05, **p < 0.01, ***p < 0.001.
predictive factor for cognitive decline only in the PD group. In
fact, only in PD patients lower CSF Aβ42 levels were correlated to
a more marked decrease in MMSE and MoCA scores at follow-
up. The finding of reduced CSF Aβ42 levels in PD patients is
quite controversial, being reported in some (Sjögren et al., 2002;
Zhang et al., 2008; Alves et al., 2010) but not in other papers
(Pøikrylová Vranová, 2010; Siderowf et al., 2010; Leverenz et al.,
2011).
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Table 4 | Spearman’s rank correlations between CSF biomarkers, age, disease duration, and clinical scores in PD group.
Age Disease duration Hoehn and Yahr scale MMSE score decrease MoCA score decrease
PD Aβ42 −0.28 −0.13 −0.19 −0.52*** −0.45**
t-tau 0.31* 0.04 0.39** 0.18 0.08
p-tau 0.24 0.10 0.09 −0.10 −0.16
Aβ42/t-tau ratio −0.42** −0.11 −0.50*** −0.37* −0.26
t-α-syn 0.00 0.30 0.10 0.06 −0.03
o-α-syn −0.26 −0.17 −0.14 −0.07 −0.07
o/t-α-syn ratio −0.18 −0.27 −0.12 −0.02 0.05
OND Aβ42 −0.37 −0.01 −0.38
t-tau 0.18 0.17 0.09
p-tau 0.18 −0.26 0.26
Aβ42/t-tau ratio −0.43* −0.12 −0.24
t-α-syn −0.41* −0.37 −0.07
o-α-syn −0.02 −0.20 −0.41
o/t-α-syn ratio 0.33 0.02 −0.24
*p < 0.05, **p < 0.01, ***p < 0.001.
Table 5 | Logistic regression analysis of multiple CSF biomarkers between PD and OND.
Estimate SE p-value Accuracy measures
Intercept −2.540 0.882 – Sens = 0.70 LR+ = 4.40
Aβ42/t-tau ratio 0.405 0.162 0.012 Spec = 0.84 LR− = 0.35
o/t-αsyn ratio 28.514 11.124 0.010 PPV = 0.89 DOR = 12.52
NPV = 0.62 AUC = 0.82 (95%CI = 0.73–0.92)
FIGURE 2 | Aβ42/t-tau and o/t-α-syn ratios in PD and OND.
(A) Scatterplot: the dashed line represents a partition of the o/t-α-syn
and Aβ42/t-tau space such that below the line the model predicts OND,
above the line the model predicts PD (B) ROC curves of Aβ42/t-tau and
o/t-α syn ratios and the fitted values of the multivariable logistic
regression model.
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Table 6 | Linear regression analyses of cognitive decline in PD cohort.
Estimate SE p-value
MMSE score Intercept 3.60 – –
decrease 1/Aβ42 1139.92 329.08 0.012
MMSE score at
baseline
−0.17 0.08 0.038
Follow-up
duration (years)
0.18 0.08 0.029
MoCA score Intercept 2.75 – –
decrease 1/Aβ42 1395.25 482.93 0.007
MoCA score at
baseline
−0.08 0.09 0.387
Follow-up
duration (years)
0.22 0.11 0.048
A clear positive association was also observed between t-tau
and t-α-syn in PD group. These findings are consistent with the
observation of Kang and coworkers, describing the occurrence of
lower CSF levels of t-tau and t-α-syn in PD patients. A reasonable
explanation may be the mutual interaction of the two molecules,
leading to a reduced release of tau in CSF. The discriminative
power between PD and OND significantly improved when con-
sidering both o/t-α-syn ratio and Aβ42/t-tau ratio, as shown by
the logistic regression analysis, and further illustrated in Figure 2.
This confirms that the combination of several biomarkers is more
helpful than single biomarkers for adding diagnostic accuracy
of PD.
About the predictive value of CSF biomarkers for cognitive
decline in PD, our study confirmed the specific role of low CSF
levels of Aβ42 in this pathological condition; no other biomarker
was significantly associated to this outcome measure. For assess-
ing cognitive function along time, we used both MMSE and
MoCA (Gill et al., 2008). Both neuropsychological instruments
showed to be related to CSF Aβ42 levels, i.e., lower the CSF
Aβ42 levels, greater the decrease in MMSE and MoCA scores.
The same holds true for Aβ42/t-tau ratio with respect to MMSE.
Multivariate analysis (adjusting for follow-up time and baseline
measurements) confirmed that low CSF Aβ42 levels are indepen-
dent predictor of cognitive decline in PD, either measured by
MMSE or MOCA.
In conclusion, this study further contributes to the evidence of
the usefulness of CSF biomarkers for PD diagnosis and prognosis.
Major points are the need to combine several CSF biomark-
ers for improving the diagnostic accuracy, and the confirmed
role of low CSF Aβ42 levels as independent predictor of cogni-
tive decline in PD. Longitudinal studies measuring biomarkers
and clinical parameters over several years represent a major
contribution in this field. Analogously to the longitudinal AD
Neuroimaging Initiative (ADNI, http://adni-info.org/) in AD,
the Parkinson’s Progression Markers Initiative (PPMI, http://
ppmi-ifo.org/) will give important knowledge in the field of PD,
thanks to the measurement of several CSF, blood, and imag-
ing biomarkers in early de novo PD followed up for several
years.
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